Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.
about
Multimorbidity in rheumatic conditionsAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapyDrug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Complement C3 Is the Strongest Predictor of Whole-Body Insulin Sensitivity in Psoriatic Arthritis.Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infectionLong term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritisIncreased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1α expression in peripheral blood mononuclear cellsSwitching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritisRepurposing existing drugs for cardiovascular risk management: a focus on methotrexate
P2860
Q28070338-54FA976E-677C-401A-9C16-A71087B76AF4Q28074393-BB34DADB-830B-444C-A8BD-AE702E7AB288Q33993099-9445CFC0-DAC2-44E3-B25A-4D429CD9759DQ36140527-23C3356F-0DB7-4AD5-AF2C-107523C577BEQ37268868-E30A6CD3-F894-43BC-A88A-5EB3EFBB91ADQ37655910-4D904CAC-4124-4117-91B3-9877176EDB49Q37724124-C98FD3F4-AFDE-40D5-86D0-12A5C65AE4A0Q39616530-FD23E121-83D7-46DA-8E19-D3003BFA7541Q41784804-443DD7E2-E063-4165-94C8-425D2FEBD2F8Q47114261-34B6EFC8-7F44-4C9A-BD61-86AE6EB79935Q47218445-1DC8F833-94A3-49A8-A23B-E2124ADE7CB6Q50109832-730954B5-505E-4EF9-A59A-BCB36A2435DBQ50127587-D30CF9CB-1CD1-4F39-B822-7B4943A3298DQ58727105-5DAAF0AD-CE9D-4860-86E0-82898208CE7DQ59135667-6D7CE0B9-B42E-434F-A63B-82A11500DFCB
P2860
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Impact of 24-month treatment w ...... psoriatic arthritis patients.
@en
Impact of 24-month treatment w ...... psoriatic arthritis patients.
@nl
type
label
Impact of 24-month treatment w ...... psoriatic arthritis patients.
@en
Impact of 24-month treatment w ...... psoriatic arthritis patients.
@nl
prefLabel
Impact of 24-month treatment w ...... psoriatic arthritis patients.
@en
Impact of 24-month treatment w ...... psoriatic arthritis patients.
@nl
P2093
P2860
P50
P1476
Impact of 24-month treatment w ...... psoriatic arthritis patients.
@en
P2093
Antonio Del Puente
Augusta Ortolan
Mariangela Atteno
Paolo Caso
Roberta Ramonda
Ugo Fiocco
P2860
P304
P356
10.1007/S10067-013-2369-1
P577
2014-06-01T00:00:00Z